Genece Health

We feel honored to stand with the community of individuals and teams that are passionate about improving care and preventing cancer.

Thanks to our 800+ friends who posed for our photo mosaic wall at AACR, which enabled a $4000 donation to the AACR Foundation. We are proud to support such a great cause! #AACR2024

Come learn more about our unique bioinformatics approach in poster section 36 Abstract 4928 this morning from 9 am to 12:30 pm with our lead data scientist, Dr. Michael Wang , and see our proof-of-concept breast cancer data in poster section 32 Abstract 4796 with one of our Lab Scientists, Molly D. Smith.

Excited to debut our Genece Lung Cancer Assay performance today from 1:30 to 5 pm in poster section 33 Abstract 3448. Stop by and learn more with our head of R&D, Bryan Leatham. #AACR2024

Come talk with Dr. Michael Salmans today from 1:30 to 5 pm in Poster Section 14 Abstract 323 to learn how the Genece assay design maintains high performance with as low as a 1 ng cfDNA input and variable sequencing depths. Much lower input, and lower cost, than traditional liquid biopsy. #AACR2024

Kicking off AACR with a run supporting cancer research! Visit our booth, #2648, to see how our deep learning AI elevates liquid biopsy results. #AACR2024

We are excited to welcome Dr. Marra Francis, MD, FACOG and her passion for women’s health as the Chief Medical Officer of Genece Health! https://lnkd.in/geH_n54Q

Nearly 2 million indeterminant lung nodules are identified each year. A staggering 69% of these have a malignancy risk ranging from 5 to 65%, making them difficult for physicians to triage. There is a critical need for enhanced diagnostic tools to provide more precise characterizations of these ambiguous findings. Genece Health is proud to introduce high-sensitivity lung cancer detection data, offering a significant advancement in the clarity and confidence of diagnostic outcomes. Learn more at #aacr2024 Poster 3448.  

Our proprietary combination of fragment analysis, end-motif sequencing, and deep learning delivers exceptionally high sensitivity and specificity – see more at poster 4928 at #AACR2024

We are uniquely focused on Targeted Screening. Physicians can be frustrated by the gaps in traditional cancer screening paradigms for lung and breast cancer. Traditional imaging results from mammography and CT scans can be indeterminate, making treatment decisions difficult. There is a large, unmet need for tools to add clarity to imaging results. By testing for ctDNA in tandem with imaging, we enable physicians to have more confidence in their treatment decisions.